NewslettersPulmonary Cell NewsFDA Approves Genentech’s Alecensa as First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung CancerBy Noshin Noorjahan - April 24, 20240139Genentech, announced that the US FDA has approved Alecensa® for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, as detected by an FDA-approved test.[Genentech]Press Release